Canada - English - Health Canada

merck canada inc - boceprevir; ribavirin; peginterferon alfa-2b - capsule - 200mg; 200mg; 100mcg - boceprevir 200mg; ribavirin 200mg; peginterferon alfa-2b 100mcg - interferons

Canada - English - Health Canada

merck canada inc - boceprevir; ribavirin; peginterferon alfa-2b - capsule - 200mg; 200mg; 120mcg - boceprevir 200mg; ribavirin 200mg; peginterferon alfa-2b 120mcg - interferons

Canada - English - Health Canada

merck canada inc - boceprevir; ribavirin; peginterferon alfa-2b - capsule - 200mg; 200mg; 150mcg - boceprevir 200mg; ribavirin 200mg; peginterferon alfa-2b 150mcg - interferons

Israel - English - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - solution for injection - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b - besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.

Israel - English - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - solution for injection - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b - besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.

European Union - English - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycythemia vera - immunostimulants, - besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.

Australia - English - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - peginterferon alfa-2a, quantity: 180 microgram - injection, solution - excipient ingredients: acetic acid; water for injections; sodium acetate; sodium chloride; polysorbate 80; benzyl alcohol - chronic hepatitis c (chc): the combination of pegasys and copegus is indicated for the treatment of chronic heptitis c in patients who have received no prior interferon therapy (treatment naive patients) and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin. the combination of pegasys and copegus is also indicated for the treatment of chronic hepatitis c in patients with clinically stable human immunodeficiency virus (hiv) co-infection who have previously not received interferon therapy. pegasys monotherapy is indicated for the for the treatment of chronic heptitis c in treatment naive patients (see dosage and administration; chronic hepatitis c: treatment naive patients). patients must be 18 years of age or older and have compensated liver disease. chronic hepatitis b (chb): pegasys is indicated for the treatment of chronic heptitis b in adult patients with evidence of viral replication and liver inflammation and compensated liver disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - peginterferon alfa-2a, quantity: 135 microgram - injection, solution - excipient ingredients: water for injections; sodium acetate; acetic acid; polysorbate 80; sodium chloride; benzyl alcohol - chronic hepatitis c (chc): the combination of pegasys and copegus is indicated for the treatment of chronic heptitis c in patients who have received no prior interferon therapy (treatment naive patients) and patients who have failed previous treatment with interferon alfa (pegylated or non-pegylated) alone or in combination therapy with ribavirin. the combination of pegasys and copegus is also indicated for the treatment of chronic hepatitis c in patients with clinically stable human immunodeficiency virus (hiv) co-infection who have previously not received interferon therapy. pegasys monotherapy is indicated for the for the treatment of chronic heptitis c in treatment naive patients (see dosage and administration; chronic hepatitis c: treatment naive patients). patients must be 18 years of age or older and have compensated liver disease. chronic hepatitis b (chb): pegasys is indicated for the treatment of chronic heptitis b in adult patients with evidence of viral replication and liver inflammation and compensated liver disease.

Philippines - English - FDA (Food And Drug Administration)

schering-plough corporation - pegylated interferon alfa 2b - powder for injection sc - 50mcg

Philippines - English - FDA (Food And Drug Administration)

schering-plough corp - pegylated interferon alfa 2b - powder for injection sc - 120mcg